OPKO Health Inc..
OPK.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
OPKO Health Inc. is a diversified healthcare company. It operates primarily in the diagnostics and pharmaceuticals industries. The company's diagnostics business includes BioReference Laboratories, a clinical laboratory providing diagnostic testing services. Its pharmaceutical segment focuses on dev...Show More
Better Health for All
20
OPKO Health's core business is dedicated to improving health outcomes, focusing on next-generation solutions for serious diseases. Its product portfolio includes FDA-approved NGENLA and marketed RAYALDEE, and its BioReference Laboratories subsidiary serves approximately 11 million patients annually.
1
The company also conducts research into multispecific therapies for cancers and infectious diseases. Furthermore, OPKO's BioReference Laboratories collaborates with SOMOS to improve health outcomes for over 700,000 Medicaid beneficiaries and underserved populations in New York City.
2
In response to global health crises, OPKO's ModeX subsidiary received $110 million in BARDA funding for the development of COVID and influenza multispecific antibodies, generating $7.0 million in revenue from this contract in Q1 2025.
3
Fair Money & Economic Opportunity
0
OPKO Health Inc. is a healthcare company focused on diagnostics and pharmaceuticals. The 'Fair Money & Economic Opportunity' value assesses financial institutions that lend, insure, move, or store money. As OPKO Health does not offer consumer financial products or services such as lending or deposit accounts, most KPIs under this value are not applicable to its core business model. The company provides patient assistance programs for its medication, Rayaldee, to help individuals afford prescriptions, including for uninsured patients and those with Low-Income Subsidies for Medicare Part D.
1
However, these are healthcare access initiatives, not financial services. No evidence was found regarding financial product pricing, fee structures, lending compliance, or wealth-building outcomes for financial customers. Information on profit reinvestment in community finance was not provided.
Fair Pay & Worker Respect
0
OPKO Health Inc.'s CEO to median employee pay ratio was 47:1 in 2024.
1
The company's overall employee rating on Glassdoor is 2.8 out of 5 stars, based on 68 reviews, which is 20% below the industry average for the Pharmaceutical & Biotechnology industry.
2
Employee reviews on Indeed, based on 9 reviews, show an overall rating of 3.4 out of 5 stars.
3
The compensation and benefits rating on Glassdoor is 2.4 out of 5 stars, showing a 4% improvement.
4
Employee feedback includes positive aspects such as good starting base and health benefits, alongside negative comments regarding low salary, limited professional growth, and issues with management and culture.
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points were found in the provided articles for any of the Fair Trade & Ethical Sourcing KPIs. While OPKO has adopted a conflict minerals provision for supplier agreements
1
and its products contain potential conflict minerals
2
, the articles do not provide a percentage of supplier contracts with ethical clauses or the share of spend on high-risk materials. Therefore, all KPIs are omitted due to lack of evidence.
Honest & Fair Business
0
No specific, concrete evidence was found in the provided articles to score any of the KPIs against the 'Honest & Fair Business' value. While a $16.5 million settlement with the SEC for securities law violations was noted, this occurred in May 2020, which falls outside the 'past three years' timeframe required by the 'regulatory_fines_3y' KPI.
1
Information regarding transparency index scores
2
, whistleblower policies
3
, financial restatements within the last five years
4
, audit coverage
5
, ESG controversy scores
6
, complaint resolution times
7
, board conflict-free percentages
8
, anti-corruption policies
9
, or third-party verification
10
was not provided with sufficient detail or recency to meet the rubric's criteria.
Kind to Animals
-50
OPKO Health Inc. conducts animal testing for its medical analysis and clinical research
1
, including pre-clinical trials for various pharmaceutical products
2
. These studies involve animal models such as mice, sheep, hemophilia animal models, and obese/diabetic animal models to assess drug efficacy, survival rates, and disease mechanisms
3
. The company's documents do not explicitly state an animal testing policy
4
.
No War, No Weapons
0
OPKO Health's 2014 Conflict Minerals Report states that the company does not purchase raw ore or unrefined conflict minerals, nor does it make purchases from the Covered Countries (conflict-affected regions).
1
No other explicit, quantitative evidence was found in the provided articles to assess OPKO Health Inc. against the remaining 'No War, No Weapons' ethical value KPIs.
Planet-Friendly Business
10
In 2022, OPKO Health's total Scope 1, 2, and 3 greenhouse gas emissions were 12,590 metric tons of CO2, comprising 4,567 metric tons from research facilities, 1,234 metric tons from transportation, and 6,789 metric tons from manufacturing.
1
The company has a goal to reduce its total greenhouse gas emissions by 20% by 2026.
2
In 2022, OPKO Health conducted 14 environmental impact assessments.
3
Respect for Cultures & Communities
0
The provided articles do not contain specific, concrete data points or facts relevant to any of the KPIs for 'Respect for Cultures & Communities'. While one article notes that no specific regulatory actions, violations, fines, or compliance issues related to this value are mentioned
1
, this is an absence of information rather than explicit evidence of zero incidents, the existence of specific protocols, or partnerships. Therefore, no KPIs can be scored based on the available evidence.
Safe & Smart Tech
0
OPKO Health Inc. has faced significant regulatory challenges, including a $10 million settlement
1
and a five-year Corporate Integrity Agreement effective July 2022,
2
related to alleged fee-for-service claims to federal and state healthcare programs. Additionally, the company settled with the Texas Medicaid Office of the Inspector General for $4.2 million in November 2023
3
and received a Civil Investigative Demand from the U.S. Department of Justice regarding potential False Claims Act and Anti-Kickback Statute violations. Regarding data security, a data breach at a third-party vendor (AMCA) between August 2018 and March 2019
4
affected approximately 422,600 of its BioReference Laboratories patients,
5
exposing credit card, bank account, and personal information.
6
However, recent reports from 2024 and 2025 indicate no material breaches or cybersecurity issues directly affecting the company within the past three years. OPKO maintains industry certifications such as SOC 2 Type 2 and PCI DSS attestations.
7
The company conducts regular privacy and security training for employees
8
and performs annual vulnerability and penetration tests and data privacy and protection reviews by third-party experts, with no significant findings identified.
9
Patients have rights to access, amend, and receive an accounting of their protected health information,
10
and BioReference Laboratories provides direct patient access to health information and bill payment through a portal.
11
The company also conducts regular assessments and updates of technical safeguards based on ongoing vulnerability analyses and threat intelligence.
12
Zero Waste & Sustainable Products
0
No specific, concrete, company-wide data points were found in the provided articles for any of the 'Zero Waste & Sustainable Products' KPIs. Several articles explicitly state a lack of information regarding waste management, sustainable products, or zero-waste initiatives for OPKO Health Inc.
1
While a subsidiary, EirGen Pharma, adopted a 100% curbside recyclable and repulpable shipping solution, this initiative was not stated to be company-wide for OPKO Health Inc.
2